Syfovre Retinal Vasculitis Eye Inflammation Side Effects Causing Vision Loss
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
We are currently investigating Syfovre retinal vasculitis eye inflammation cases as possible Syfovre drug injury lawsuits for patients. These lawsuits would be against Apellis Pharmaceuticals, Inc., the drug company responsible for Syfovre.
Syfovre is an eye-injection drug treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It was approved by the FDA on February 17, 2023.
Syfovre side effects include occlusive retinal vasculitis, which is a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and could potentially cause blindness. There have also been reported cases of non-occlusive retinal vasculitis and other types of eye inflammation.
To date, all reported Syfovre adverse events causing these vision problems began one to two weeks after a patient’s first Syfovre injection.
UPDATE: From this February 28, 2024, Fierce Pharma news report, “Apellis cites current challenges with Syfovre launch but bright prospects in the long term“, we get the most recent explanation from Apellis Pharmaceuticals about the cause of Syfovre eye-related side effects:
As for Syfovre’s safety issue — which Apellis originally speculated was a needle problem for the injected drug — the company now “firmly” believes it is caused by a pre-existing allergy toward polyethylene glycol, Francois said. The incidence of users developing vasculitis remains at .01% per injection, the company said. [Emphasis added.]
(2/28/24)
Free Syfovre Case Evaluation
We encourage you to submit a Syfovre Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible Syfovre drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his more than 20 years of experience handling drug injury cases.
Most Recent Article About Syfovre
Syfovre’s Risks Keep It Off The Market In Europe, Again, With June 2024 Decision
As we have been reporting since July 2023, Syfovre’s risks include serious eye side effects such as occlusive retinal vasculitis, a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and potentially causing blindness. There have also been cases of non-occlusive retinal vasculitis and other types of eye inflammation.
In late June 2024, Europe’s drug regulator did not approve Syfovre for a second time, meaning that Syfovre is still unavailable in Europe. In the US, Syfovre was approved by the FDA in February 2023.
From this Fierce Pharma June 28, 2024 article, “EU’s drug regulator again rejects Apellis’ eye med….”, we get the latest on what is happening with Syfovre in Europe:
For the second time in six months, Europe’s Committee for Medicinal Products for Human Use (CHMP) has given a thumbs down to Apellis’ Syfovre for the treatment of patients with geographic atrophy (GA) caused by age-related macular degeneration….
“Although the studies showed that Syfovre slowed the growth of geographic atrophy lesions, this did not lead to clinically meaningful benefits for patients,” the CHMP said. “It was noted that benefits of a treatment should impact patients’ everyday functioning, and this was not demonstrated in the studies.”
“In terms of safety,” the CHMP continued, “regular injections into the eye carry a significant risk of adverse events, including the development of other forms of AMD or inflammation in the eye, that could further worsen vision.”
In January of this year, the CHMP adopted its first negative opinion on Syfovre….
To read more of this article, click below:
We have been monitoring this Syfovre drug safety issue since July 2023 on Drug Injury Watch, and these are the four most recent articles:
- Syfovre Retinal Vaso-occlusive Vasculitis Case Report Involving 78-year Old Woman With Vision Loss (4/24/2024)
- Syfovre Case Report: Occlusive Retinal Vasculitis Shortly After Patient’s First Syfovre Injection (3/6/2024)
- Syfovre Safety Issues Need More Attention Before This Relatively New Eye Drug Gets Widely Prescribed (12/27/2023)
- Syfovre Update: New Warnings About Retinal Vasculitis and/or Retinal Vascular Occlusion After Syfovre Injections (12/4/2023)
We continue to investigate possible Syfovre drug injury lawsuits for patients who developed retinal vasculitis or retinal vascular occlusion with resulting vision loss or blindness after their Syfovre injection.
[Read article in full at original source]Earlier articles about Syfovre by attorney Tom Lamb on the Side Effects Blog:
- Syfovre: Loss of Vision 11 Days After Receiving Syfovre Injection
- Syfovre Eye Injury Cases Update One Year After First Reports: “Uncertain”
- At Least 13 Patients Had Syfovre Retinal-Related Vision Loss in 2023
- Syfovre Side Effects Issue Raised In December 2023 JAMA Viewpoint Piece
- New Syfovre Warnings for Retinal Vascular Occlusion and Retinal Vasculitis
- Syfovre Eye Side Effects Cases Reported at Ophthalmology Meeting
- Syfovre Retinal Vasculitis Cases Caused by Injection Kits With a 19-gauge Filter Needle?
- Syfovre Eye Injections Adverse Reactions Update August 2023
- Syfovre Vision Loss Cases Reported In Patients After First Injection